Oxford BioMedica plc (LON:OXB) had its price objective lifted by N+1 Singer from GBX 7.80 ($0.10) to GBX 8.70 ($0.11) in a research report report published on Thursday. N+1 Singer currently has a hold rating on the biopharmaceutical company’s stock.

Several other equities research analysts have also recently weighed in on OXB. Jefferies Group LLC reaffirmed a buy rating and set a GBX 13 ($0.17) price objective on shares of Oxford BioMedica plc in a research report on Thursday, July 13th. Shore Capital reaffirmed a not rated rating on shares of Oxford BioMedica plc in a research report on Thursday, July 13th.

Shares of Oxford BioMedica plc (OXB) opened at 8.58 on Thursday. The firm’s market cap is GBX 264.61 million. Oxford BioMedica plc has a 12 month low of GBX 2.98 and a 12 month high of GBX 11.50. The company’s 50 day moving average is GBX 7.58 and its 200-day moving average is GBX 5.41.

TRADEMARK VIOLATION NOTICE: “N+1 Singer Boosts Oxford BioMedica plc (OXB) Price Target to GBX 8.70” was first posted by Daily Political and is owned by of Daily Political. If you are reading this report on another site, it was stolen and reposted in violation of US & international copyright law. The legal version of this report can be accessed at https://www.dailypolitical.com/2017/07/30/n1-singer-boosts-oxford-biomedica-plc-oxb-price-target-to-gbx-8-70.html.

In other news, insider Martin Diggle acquired 660,000 shares of the business’s stock in a transaction that occurred on Thursday, July 13th. The stock was acquired at an average price of GBX 9 ($0.12) per share, with a total value of £59,400 ($77,384.05). Also, insider Lorenzo Tallarigo acquired 49,033 shares of the business’s stock in a transaction that occurred on Friday, June 23rd. The shares were purchased at an average cost of GBX 5 ($0.07) per share, with a total value of £2,451.65 ($3,193.92). Insiders have purchased 1,011,980 shares of company stock valued at $8,448,961 in the last ninety days.

About Oxford BioMedica plc

Oxford BioMedica plc is a gene and cell therapy company. The Company is engaged in lentiviral vector and cell therapy research, development and production. The Company’s segments include Partnering, and R&D. The Partnering segment provides lentiviral vector bioprocessing and process development services to partners.

Receive News & Ratings for Oxford BioMedica plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford BioMedica plc and related companies with MarketBeat.com's FREE daily email newsletter.